ResMed Inc. stock gains after RBC upgrade and conference margin outlook
Published on 09/15/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ResMed Inc. stock (ISIN US7611521078) traded around USD 222.84 on Nasdaq on September 14, 2026, up about 2.1% from a previous close of USD 218.27, according to Nasdaq-linked price data. The move gained momentum on September 15, 2026, when analysts highlighted both an upgraded rating and a stronger long-term margin story for the sleep and respiratory device maker.
RBC upgrade and price target lift ResMed Inc. stock
On September 15, 2026, ResMed Inc. stock reacted to a rating change at RBC Capital Markets, which raised its recommendation from Sector Perform to Outperform and increased its price target from USD 244 to USD 262 per share, implying a mid-teens upside from recent trading levels, as GuruFocus reported on September 15, 2026. A Dow Jones newswire summary on the same day confirmed the new USD 262 target and the Outperform rating, underscoring that RBC now sees ResMed better positioned for growth than many healthcare peers, according to Dow Jones Newswires on September 15, 2026.
Financial media noted that the shares rose by roughly 3% to 5% intraday around the announcement, highlighting that the upgrade came after RBC reviewed the latest quarterly numbers and saw room for high single-digit earnings-per-share growth over the next three years even if a key competitor returns to the US market, as CNBC summarized on September 15, 2026. For retail investors, the combination of a higher target and a more optimistic multi-year earnings view is a key part of the current ResMed Inc. stock story.
Conference guidance: growth range and margin expansion
Beyond the analyst call, ResMed used a major industry event on September 15, 2026 to spell out its growth and margin expectations into fiscal 2027 and beyond. At the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, the company outlined that it is entering fiscal 2027 with formal guidance for the first time, aiming for top-line growth in the high single-digit percentage range and a steady expansion in profitability, according to Investing.com on September 15, 2026.
ResMed told investors that its guidance framework implies approximately 6.3% to 8.3% revenue growth for fiscal 2027, with an underlying core constant-currency revenue growth assumption of 5% to 7% once certain non-core items are stripped out, which lands squarely in the high single-digit range the company has highlighted in previous discussions, as Investing.com reported on September 15, 2026. Management stressed that this growth is to be driven by rising patient demand for sleep apnea and respiratory care solutions, product innovation and deeper digital engagement with patients and providers.
On margins, ResMed emphasized that gross margin has expanded by more than 500 basis points over the past three years and that it expects low double-digit basis-point improvement in gross margin each fiscal year through 2030, supported by scale and efficiency gains, even as it continues to face cost pressure from freight, logistics and components, as Investing.com noted on September 15, 2026. Historically, that more than 500 basis point improvement over three years gives investors a numerical benchmark for how much profitability has already moved, while the incremental annual expansion target signals that margins are expected to keep rising from current levels.
Market capitalization, consensus and valuation signals
ResMed Inc. stock currently trades with a market capitalization of about USD 32.16 billion, placing the company among the 800 largest listed firms worldwide by equity value; this value was reported for September 14, 2026 and reflects a modest 9.96% decline in market cap for 2026 versus the prior year, according to data compiled by CompaniesMarketCap as of September 2026. At a share price around USD 222.99 on September 14, 2026, ResMed stood roughly midway between its reported one-year low of USD 180.26 and one-year high of USD 284.87 mentioned in recent analyst and holdings reports, giving investors a sense of how far the stock remains below its 52-week peak, as MarketBeat summarized on September 15, 2026.
Consensus data show that the sell-side view on ResMed remains mixed despite the RBC upgrade. As of early September 2026, brokerages collectively assigned the stock an average rating of Hold and an average price target of USD 248.92, with individual targets ranging from USD 175.00 at the low end to USD 320.00 at the high end, according to an overview cited on September 15, 2026 by Mitrade. Another analyst aggregation reported a consensus rating of Hold and a consensus price target of around USD 240.31 based on coverage by six Buy-rated and ten Hold-rated analysts, reinforcing that, even after RBC's move, the broader community still sees the shares as fairly valued with modest upside, as MarketBeat reported on September 15, 2026.
Valuation tools confirm that there may still be room for re-rating. One fundamental analysis platform calculated a fair value estimate of USD 267.59 for ResMed based on its GF Value metric, suggesting that at a trading price of about USD 233.06, the stock is undervalued by roughly 12.9%, as GuruFocus detailed on September 15, 2026. Another data provider put ResMed's market capitalization at USD 32.9 billion and highlighted a price-to-earnings ratio around 22 times, arguing that the combination of earnings growth, GLP-1-related tailwinds for sleep apnea diagnosis and margin expansion could justify a higher multiple over time, as Investing.com explained on September 15, 2026.
Risks, earnings expectations and what to watch next
Analyst commentary also points to several risk factors that investors in ResMed Inc. stock need to track. RBC's note, as summarized by CNBC, explicitly assumes that a major competitor in sleep and respiratory devices returns to the US market in fiscal 2028, which would increase price competition and potentially slow margin expansion, according to CNBC on September 15, 2026. At the Morgan Stanley conference, management also acknowledged ongoing cost pressures in freight, logistics and components, meaning that the projected low double-digit basis-point annual improvements in gross margin will require continued execution on efficiency and sourcing, as Investing.com reported on September 15, 2026.
Forward-looking consensus figures provide additional context for how the market currently frames growth. One earnings overview indicated that the consensus estimate for ResMed's fiscal 2027 earnings per share stands at USD 12.02, slightly down by 0.1% over the past 30 days, while consensus fiscal 2026 revenue is estimated at USD 5.87 billion, up 3.8% from the year-ago reported figure, as Zacks Investment Research summarized on September 15, 2026. That 3.8% year-on-year revenue increase forecast is a relatively modest growth rate compared with the high single-digit revenue trajectory that ResMed laid out at the Morgan Stanley conference, illustrating how guidance and consensus are gradually converging but still leave room for positive or negative surprises.
Several other banks have adjusted their views following recent results and guidance. One analyst note reported that KeyBanc raised its price target on ResMed to USD 267 and reiterated an Overweight rating based on confidence in the fiscal 2027 outlook, while another house, Rothschild Redburn, initiated coverage with a Neutral rating and a USD 230 target, as Investing.com reported on September 15, 2026. Taken together with the RBC move to USD 262, these targets cluster in a range roughly 3% to 20% above the current share price, giving a numerically defined band of expected upside that investors can compare against their own assumptions on growth and margin resilience.
ResMed Inc. stock price level and trading context
ResMed Inc. stock most recently closed near USD 222.84 on Nasdaq on September 14, 2026, about 2.1% above the prior close of USD 218.27, with intraday data showing the shares trading around USD 232.68 and up more than 4% in fair-value terms during the session on September 15, 2026, according to price information compiled by major stock portals. That leaves the stock still below its reported one-year high of USD 284.87 and above its one-year low of USD 180.26, situating the current level roughly one third of the way up the 52-week range, based on recent holdings and range data cited by MarketBeat on September 15, 2026. For investors, the key question is how quickly ResMed can translate its high single-digit revenue growth and low double-digit basis-point margin improvements into earnings growth that justifies the upgraded price targets now emerging from RBC and others.
ResMed Inc. stock key data
- Company: ResMed Inc.
- ISIN: US7611521078
- Ticker: RMD
- Trading venue: Nasdaq
- Price (as of September 14, 2026): 222.84 USD
- Market capitalization: 32.16 billion USD (as of September 14, 2026)
- Sector / Industry: Healthcare equipment and services
- Index membership: S&P 500
